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Abstract
Objectives To investigate risk factors for retinopathy of prematurity (ROP) in a newly established ROP screening and
management programme in Rwanda, Africa.
Methods In this multi-centre prospective study 795/2222 (36%) babies fulfilled the inclusion criteria (gestational age (GA)
< 35 weeks or birth weight (BW) < 1800 g or unstable clinical course), 424 (53%) of whom were screened for ROP. 270 died
before the first screening. ROP and treatment-warranted ROP were classified using the revised International Classification of
ROP (2005). Data on maternal and perinatal risk factors were collected from daily neonatal notes.
Results 31 babies (7.3%, CI 5.0–10.2) developed any ROP, 13 of whom (41.9%, CI 24.5–60.9) required treatment. ROP
was seen in six neonates with GA > 30 weeks and BW > 1500 g, one of whom required treatment. In univariate analysis the
following were associated with any ROP: increasing number of days on supplemental oxygen (OR 2.1, CI 1.5–3.0, P <
0.001), low GA (OR 3.4, CI 1.8–6.4, P < 0.001), low BW (OR 2.3, CI 1.5–3.4, P < 0.001), at least one episode of
hyperglycaemia ≥ 150 mg/dl (OR 6.6, CI 2.0–21.5, P < 0.001), blood transfusion (OR 3.5, CI 1.6–7.4, P < 0.001) or sepsis
(OR 3.2, CI 1.2–8.6, P= 0.01). In multivariate analysis longer exposure to supplemental oxygen (OR 2.1, CI 1.2–3.6, P=
0.01) and hyperglycaemia (OR 3.5, CI 1.0–12.4, P= 0.05) remained significant.
Conclusions ROP has become an emerging health problem in Rwanda, requiring programmes for screening and treatment.
ROP screening is indicated beyond the 2013 American Academy guidelines. Improved quality of neonatal care, particularly
oxygen delivery and monitoring is needed.
Introduction
Retinopathy of prematurity (ROP) is a potentially blinding
eye condition, associated with abnormal retinal vascular
proliferation at the boundary of vascularised and avascular
peripheral retina of prematurely born babies. This can lead
to retinal detachment and visual loss [1]. Regular screening
and timely treatment are essential in improving anatomical
and functional outcomes and should be part of routine
These authors contributed equally: Francis Mutangana,
Charles Muhizi
Meeting presentation: The work has been accepted and presented as
Poster Presentation (Poster 186-B0340, abstract #2906642) for the
2018 ARVO Annual Meeting in Honolulu.
* Stefan De Smedt, MD PhD
dr.stefan.desmedt@gmail.com
1 Ophthalmology, King Faisal Hospital, Kigali, Rwanda
2 Ophthalmology, CHUB, Huye, Rwanda
3 Ophthalmology, CHUK, Kigali, Rwanda
4 Ophthalmology, Kabgayi Eye Hospital, Rwanda Charity Eye
Hospital, Southern Province, Rwanda
5 Pediatrics, King Faisal Hospital, Kigali, Rwanda
6 Pediatrics, CHUK, Kigali, Rwanda
7 Pediatrics, CHUB, Huye, Rwanda
8 External consultant, Mechelen, Belgium
9 Ophthalmology, KU Leuven, Leuven, Belgium
10 Ophthalmology, Epidemiology, AZ St Maarten Hospital,
Mechelen, Belgium
Supplementary information The online version of this article (https://
doi.org/10.1038/s41433-019-0529-5) contains supplementary















neonatal care. During the 1940/50s and 1970s a first and a
second epidemic of ROP blindness affected preterm babies
in high-income countries and these were associated with the
widespread use of unrestricted oxygen supplementation and
increasing survival of infants at lower gestational age (GA)
(< 28 weeks), respectively.
In the 1990s a third epidemic of blindness due to ROP was
described, principally in the middle and low income countries
of Latin America, Eastern Europe, and later Asia [2]. In 2010,
an estimated 184,700 preterm infants worldwide developed
any stage of ROP, and more than 30,000 became visually
impaired due to ROP [3]. In these middle income countries
neonatal care is rapidly expanding, leading to greater survival
of more immature, small for GA, and low-birth weight infants
[2, 4]. In addition, suboptimal neonatal care, as a result of lack
of awareness and resources, can lead to higher rates of severe
ROP not only in extremely premature infants but also in
larger, more mature infants [5, 6].
In sub-Saharan Africa, little is known about the incidence
of ROP [7–11]. A recent worldwide survey indicated that
ROP screening is very limited in Africa [12]. In Rwanda,
major advances in the survival of preterm infants have
occurred recently due to improving neonatal care [13]. As a
consequence, more extremely preterm infants are at risk of
ROP. The recent presentation of several children born
preterm with bilateral inoperable retinal detachment to an
Ophthalmology Department in Rwanda prompted us to set
up a screening system. A prospective observational study to
document the incidence and risk factors for ROP was
undertaken in Rwanda’s three major neonatal intensive care
units (NICU) with level 2 neonatal care (i.e. limited access
to ventilation and no total parental nutrition).
Subjects and methods
A risk factor study was nested within the prospective
observational study carried out in the NICUs of three ter-
tiary hospitals in Rwanda from September 2015 to July
2017. Two NICUs were located in the capital city Kigali,
i.e. King Faisal Hospital (KFH) and University Teaching
Hospital of Kigali (CHUK), and one in Huye, University
Teaching Hospital of Huye (University of Rwanda campus
Butare, CHUB).The study population were all preterm
babies admitted to these NICUs who fulfilled the inclusion
criteria, i.e. GA < 35 weeks or birth weight (BW) < 1800
grams (g) or an unstable clinical course, as indicated by the
paediatrician.
Data management
Data on potential risk factors were extracted from daily
neonatal progress notes throughout hospital admission on a
weekly basis. BW and GA were defined as categorical
variables. Exposure to supplemental oxygen was assessed
as the number of days in supplemental oxygen (categorical
variable) and method of administration, i.e. nasal cannula,
continuous positive airway pressure (CPAP) or ventilator
[10]. In cases of nasal cannula, supplemental unblended
oxygen was delivered. Initially oxygen saturation was
recorded but was felt to be too unreliable as a study vari-
able. Sepsis was defined as early or late (starting 3 or
more days after birth), necessitating antibiotic treatment for
≥ 5 days on clinical grounds and/or on the basis of a positive
blood culture, if available. Blood transfusion was defined as
the administration of adult red blood cells on one or more
occasions. Hyperglycaemia was defined as serum glyce-
mia ≥ 150 mg/dl sampled before a meal.
The first eye examination took place 4 weeks after birth.
At the beginning of the study six local ophthalmologists
were trained in ROP screening by an expert ophthalmolo-
gist during joint screening sessions. Quality control on the
screening process took place during follow-up visits. Both
monocular and binocular indirect ophthalmoscopy were
performed using a 20 or 30 dioptre lens and indentation or
Missotten–Fabri neonatal lens (Fabrilens, Lommel, Bel-
gium), depending on the preference of the attending oph-
thalmologist. This lens serves both as a magnifier and
speculum to keep the eyelids open. Retinal changes were
classified by stage, zones and the presence of plus disease
using standard photographs based on the International
Classification of ROP and Early Treatment for ROP studies
[14, 15].
The maximum severity of ROP in either eye was the
level assigned to each infant. ROP-screening was at least
every 2 weeks until vascularisation reached zone III or until
41 weeks postmenstrual age. Weekly screening was
scheduled if the vessels ended in zone I or posterior zone II,
or if there was any plus disease, or any stage 3 disease in
any zone. Treatment-warranted ROP (TW-ROP) was
defined Type 1 ROP i.e. ROP in Zone I, stage 3 without
plus disease or in Zone I, any stage with plus disease, or
ROP in Zone II, Stage 2 and 3 with plus disease [15].
Statistical analysis
Data were entered into a Microsoft Access database and
analysed using STATA-software 9.2 (STATA Corp, Col-
lege Station, TX). Statistics were presented overall and for
the subgroups any ROP, TW-ROP and no ROP. Statistical
analysis compared infants with any ROP with those with-
out. Further analysis compared infants with TW-ROP with
those without ROP. Potential risk factors were evaluated in
univariate logistic regression analyses calculating odds
ratios (OR) and 95% confidence intervals (CI) at 0.05 level
of significance. Variables which were statistically
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significant were entered into a multivariate logistic regres-
sion model using a backward stepwise method. Assuming a
prevalence of any ROP of 15% among exposed and 5%
among non-exposed to potential risk factor, a sample size of
at least 380 babies was needed to achieve 90% power at the
5% level of significance.
Ethics
The study was conducted in accordance with the Declara-
tion of Helsinki and was approved by the Rwandan
National Ethics Committee. An information sheet was read
out to parents/caregivers in Kinyarwanda, after which they
signed a consent form. All medical eye care related to ROP
was provided free of charge. This densely populated
country with a reasonably good main infrastructure has a
compulsory health insurance system, which facilitates
access to health care even for the poor.
Results
Study population
Among 2222 babies admitted to the NICUs, 795 (35.8%)
fulfilled the criteria for ROP screening, 424 (53%) of whom
were screened. Among the 371 not screened, 270 died
before the first screening, 89 were lost to follow-up after
discharge and 12 carers refused to participate.
Among the 424 screened, 370 (87.3%) babies completed
the screening process, 5 had any ROP documented when
they were lost to follow-up, and 49 were still ROP negative
when lost to follow-up before vascularisation reached zone
III or 41 weeks postmenstrual age. Of those 49 babies 3
died prior to the second eye screening and 28 were seen
twice or more.
A total of 31 babies (7.3%, CI 5.0–10.2) developed any
ROP, 13 of whom (41.9%, CI 24.5–60.9) required treatment
i.e., 3.1% (CI 1.6–5.2) of all babies screened. The demo-
graphic and pregnancy characteristics of the premature
babies screened are presented in Table 1. There were no sex
differences among babies eligible for screening and those
screened (P= 0.93 and 0.58 respectively). Most babies
(n= 279) were delivered by Caesarean section (67.7%) and
365 (87.7%) were born in the same hospital as the NICU.
The mean age of mothers of babies with ROP tended to be
higher than of babies without (mean 31.9 years (SD 6.4,
range 18–41) and mean 30.1 years (SD 5.9, range 18–48)
respectively) (Table 1).
The mean GA of those screened was 31.7 weeks (SD
2.2, range 24–37) overall and 30.1 weeks (SD 2.4, range
25–36) in the ROP group. The mean BW was 1479 g (SD
360.1, range 650–2800) overall and 1199 g (SD 303.3,
range 685–1800) in the ROP group (Table 1). ROP was
seen in six babies with GA > 30 weeks and BW > 1500 g
(19.4% of ROP-cases), one of whom required treatment
(GA 32 weeks with BW 1600 g) (Fig. 1). The neonatal
and clinical data of the babies screened are presented in
Tables 2 and 3. Sepsis occurred in 264 babies (63.6%)
overall and in 26 babies (83.9%) in the ROP group. A
serum glucose test was available for 151/424 (35.6%)
babies, as it was only routinely performed in one NICU.
Hyperglycaemia (≥150 mg/dl) was documented in 28
babies (18.5%) overall and in eight babies with ROP
(53.3%). Supplemental oxygen was given to 279 babies
(67.6%) overall and 27 babies (87.1%) in the ROP group.
Blood transfusion was needed in 117 babies (28.1%)
overall and 17 babies (54.8%) in the ROP group. Babies
not completing the screening process were not sig-
nificantly different in terms of BW, GA or any other
relevant risk factor for ROP. The 89 babies who did not
attend for the first screening were similar, except for a
significantly lower birth weight (P < 0.001).
Risk factors for any ROP
Univariate analysis comparing infants with any ROP with
those without identified the following risk factors: days in
oxygen (OR 2.1, CI 1.5–3.0, P < 0.001), low GA (OR 3.4,
CI 1.8–6.4, P < 0.001), low BW (OR 2.3, CI 1.5–3.4, P <
0.001), hyperglycaemia (OR 6.6, CI 2.0–21.5, P < 0.001),
blood transfusion (OR 3.5, CI 1.6–7.4, P < 0.001) and
sepsis (OR 3.2, CI 1.2–8.6, P= 0.01) (Table 4). The
APGAR-scores at 1, 5 and 10 min after birth were not
significantly associated with ROP. There was evidence of
a dose–response effect with increasing prematurity, low
birth weight and days in supplemental oxygen (test for
trend for each variable, P < 0.001). Oxygen administra-
tion using nasal cannula was associated with ROP (P <
0.001) but not administration via CPAP (P= 0.63). The
onset of sepsis did not significantly affect the incidence of
any ROP (P= 0.79). In the multivariate logistic regres-
sion model, days in oxygen (OR 2.1, CI 1.2–3.6, P=
0.01) and hyperglycaemia (OR 3.5, CI 1.0–12.4, P=
0.05) were the only factors that remained significant for
any ROP. Because BW and GA were highly correlated
(P < 0.001), a combined summary variable including both
was created, which was of borderline significance in this
multivariate model (OR 1.5, CI 1.0–2.2, P= 0.06). Days
in supplemental oxygen (OR 1.7, CI 1.2–2.6, P= 0.007)
remained significant but hyperglycaemia did not. No
statistically significant interactions between the retained
variables were identified, nor was there evidence of a
weak fit for the overall models (Pearson chi² test= 3.53,
P= 0.62 and Pearson chi² test= 11.97, P= 0.75,
respectively).
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Risk factors for treatment-warranted ROP
Univariate analysis identified the following risk factors for
TW-ROP: low BW (OR 5.7, CI 2.3–13.9, P < 0.001), blood
transfusion (OR 3.3, CI 1.1–10.2, P= 0.03), sepsis (P=
0.005) and some categories of low GA (OR 3.5, CI
1.0–11.9, P= 0.03) (Table 5 in supplement).
Caesarean section was protective against TW-ROP (OR
0.2, CI 0.06–0.67, P= 0.004). Decreasing birth weight
was associated with TW-ROP (score test for trend of odds
P= 0.005). The onset of sepsis did not influence
the incidence of TW-ROP (P= 0.43). In multivariate ana-
lysis the combined variable for BW and GA was an
independent risk factor (OR 2.1, CI 1.3–3.6, P= 0.002),
and Caesarean section remained protective (OR 0.2,
CI 0.06–0.71, P= 0.01).
Discussion
Until the late 20th century blindness from ROP was vir-
tually unknown in sub-Saharan Africa, apart from South
Africa where ROP accounted for 11% of blindness in
children in 1996 [5, 16]. In 1995 an early Nigerian study
found no TW-ROP, but 5.6% had any ROP [17]. A high
proportion of affected babies in this study died [17].
Table 1 Demographic and pregnancy characteristics of the premature babies screened for retinopathy of prematurity (n = 424)
All infants No ROP Any ROP Treatment-
warranted ROP
Missing data n % Missing data n % Missing data n % Missing data n %
Primipara 9 130 31.3 9 123 32.0 7 22.6 3 23.1
Received antenatal steroid 11 263 63.7 10 243 63.5 1 20 66.7 1 6 50.0
Positive HIV status mother 39 6 1.6 35 6 1.7 2 0 0.0 2 0 0.0
Method of delivery 12 12
Caesarean section 279 67.7 263 69.0 16 51.6 4 30.8
Forceps/ventouse aided delivery 0 0.0 0 0.0 0 0.0 0 0.0
unaided normal delivery 133 32.3 118 31.0 15 48.4 9 69.2
Sex of the baby 7 7
Male 192 46.0 180 46.6 12 38.7 3 23.1
Female 225 54.0 206 53.4 19 61.3 10 76.9
No. of gestations 8 8
Singleton 304 73.1 280 72.7 24 77.4 9 69.2
Twins 85 20.4 78 20.3 7 22.6 4 30.8
Triplets 27 6.5 27 7.0 0 0.0 0 0.0
Place of birth 8 8
At home 2 0.5 2 0.5 0 0.0 0 0.0
In health centre 3 0.7 3 0.8 0 0.0 0 0.0
In hospital of NICU 365 87.7 341 88.6 24 77.4 11 84.6
In other hospital 46 11.1 39 10.1 7 22.6 2 15.4
Gestational age (weeks) 7 7
<26 3 0.7 2 0.5 1 3.2 1 7.7
26 to <28 15 3.6 13 3.4 2 6.5 0 0.0
28 to <30 49 11.8 38 9.8 11 35.5 3 23.1
30 to <32 106 25.4 97 25.1 9 29.0 5 38.5
32 to <35 225 54.0 218 56.5 7 22.6 4 30.8
≥35 19 4.6 18 4.7 1 3.2 0 0.0
Birth weight (g) 9 9
<1000 31 7.5 23 6.0 8 25.8 4 30.8
1000 to <1500 191 46.0 175 45.6 16 51.6 8 61.5
1500 to <1800 115 27.7 109 28.4 6 19.4 1 7.7
≥1800 78 18.8 77 20.1 1 3.2 0 0.0
ROP retinopathy of prematurity
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However, over the last decade NICU services have expan-
ded in sub-Saharan Africa, to help achieve Goal 4 of the
U.N. Millennium Development Goals (reduction of under
5-mortality rate) [13]. Therefore, ROP is expected to have
increased, but there are limited recent data on ROP apart
from studies in South Africa [9, 10, 18, 19] and Nigeria
[11, 20].
The proportion of infants screened who developed TW-
ROP (3.1%) in our study is similar to that reported from
other lower and middle-income settings (1–7.1%)
[8, 11, 18], but the percentage developing any ROP (7.3%)
was lower (15– 47.2%) [8, 9, 11, 19, 20]. Differences in
patient selection, examination methods, and survival rates
of premature babies between low and middle-income
countries can partly explain this discrepancy
[5, 9, 20, 21], Clinically non-significant ROP stages might
also have been underreported in our study because of a
learning curve while setting up a screening programme.
Infants with ROP in our study had more days in oxygen,
lower BW, lower GA, more episodes of hyperglycaemia
and sepsis and needed more blood transfusions than those
without, similar to findings in other lower and middle-
income country studies [9].
In our study, oxygen—expressed as the number of days
of supplementation—remained a significant risk factor in
multivariate analysis. Several studies from middle-income
countries failed to identify oxygen exposure as an inde-
pendent risk factor [9, 22, 23], while others have shown that
improved oxygen delivery and adequate saturation targeting
and monitoring in infants receiving oxygen can effectively
decrease the incidence of ROP, even in rural areas [18, 24].
Assessing oxygen exposure reliably requires collecting
accurate, continuous data on oxygen saturations—which is
difficult to capture. Fluctuation in saturation levels is also
important [25], and in our study settings it was not possible
to document oxygen saturations reliably. A recent pro-
spectively planned meta-analysis of individual participant
data from extremely preterm infants recruited to large-scale
trials to compare different oxygen saturation targets, con-
firmed that the lower oxygen saturation target (range
85–89%) was associated with a lower risk of ROP treatment
compared to the higher range (91–95%), but a higher risk of
mortality [26]. Although oxygen levels are important in the
pathogenesis of ROP [27], finding a balance in oxygen
delivery to ensure adequate levels for survival [26], and at
the same time reducing the risk of ROP is not easy. In
addition, recommended oxygen saturation levels in extre-
mely low birth weight infants in the postnatal period remain
unclear [25, 26]. We found that CPAP was a safer way of
oxygen administration in terms of ROP risk than nasal
cannula as has been reported in some, but not all studies
[9, 28]. Differences in the characteristics of the study
populations may explain the differences. On the other hand,
the administration of CPAP already implicates a closer
surveillance of these patients.
In our study only a combined variable of BW and GA
remained significant in multivariate analysis and almost one
in five babies with any ROP were beyond the 2013
American Academy screening guidelines for BW (≤1500 g)
and GA (≤30 weeks) [15]. The finding that larger and more
mature infants are at risk of ROP is in accordance with
studies from other middle income countries [5], suggesting
that other modifiable risk factors play an important role in
these settings.
In our study two babies with ROP exceeded one of the
two study inclusion criteria (>1800 g BW or >35 weeks
GA), but neither developed TW-ROP. Although screening
of ROP can be a cause of stress to preterm infants and is
resource intensive [19], this observation indicates that our
wide inclusion criteria should not be narrowed in Rwanda.
Recently the US guidelines have considered slow weight
gain as a risk factor [29]. Due to the lack of total parenteral
feeding rapid weight gain rarely occurs in our study setting.
Future local audits analysing screening and treatment
data can guide refinements to these screening criteria, if the
characteristics of babies with TW-ROP change over time.
As in other studies [9, 10, 22], sepsis was a significant
risk factor for ROP. Perinatal inflammation might play a
role in the pathogenesis of ROP due to changing levels of
the cytokines involved in angiogenesis [30, 31]. Although
there is some variation depending on the definition of sep-
sis, rates can be high in NICUs with limited resources.
However, even in low-income countries effective low-
technology and low-cost nosocomial infection control
strategies can be implemented successfully to tackle sepsis
[9, 32].
Fig. 1 Distribution of retinopathy of prematurity (ROP) cases by birth
weight (BW) and gestational age (GA). The grey area represents BW
and GA beyond the American Academy 2013 screening criteria
(BW ≤ 1500 g and GA ≤ 30 weeks)
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By prospectively recruiting all consecutive preterm infants
born in the three major NICUs, we analysed a representative
sample of the prematurely born baby population of tertiary
medical centres in Rwanda. However, during the 2-year study
neonatal care was introduced in several peripheral district
hospitals, and ophthalmology departments witnessed an
increasing number of preterm infants admitted for ROP
treatment who had received care outside our study centres.
Therefore, the incidence of ROP in our study may not reflect
the overall incidence. This observation also suggests that the
epidemic of ROP has only just begun in Rwanda and that
screening needs to be expanded to these peripheral hospitals
as well. Remote ROP screening using high-resolution wide-
field imaging systems, with interpretation of the images at an
off-site reading centre, would be one way to expand coverage,
as has been implemented with success in middle and high-
income countries with a shortage of eye healthcare profes-
sionals [33]. Recently the application of less expensive sys-
tems and even smartphones (iPhone 5 combined with 20D
lens) have been described for ROP-screening [34]. This tel-
emedicine approach might be an option for Rwanda, but care
should be taken to train the photographers well, since visua-
lising the peripheral retina, which is of vital importance in
ROP screening, can be challenging.
Table 2 Neonatal and clinical categorical data of the premature babies screened for retinopathy of prematurity (n = 424)
All infants No ROP Any ROP Treatment-
warranted ROP
Missing data n % Missing data n % Missing data n % Missing data n %
Sepsis at some stage 9 9
Based on clinical picture 214 51.6 191 49.7 23 74.2 12 92.3
Confirmed by positive hemoculture 50 12.1 47 12.2 3 9.7 1 7.7
No sepsis 151 36.4 146 38.0 5 16.1 0 0.0
Timing of sepsis 12 8 4 1
Early sepsis 133 52.8 122 53.0 11 50.0 5 41.7
Late sepsis (after 3 postnatal days) 119 47.2 108 47.0 11 50.0 7 58.3
Intraventricular haemorrhage at some stage 8 8
Based on clinical picture 5 1.2 5 1.3 0 0.0 0 0.0
Confirmed by ultrasound 7 1.7 6 1.6 1 3.2 1 7.7
No intraventricular haemorrhage 404 97.1 374 97.1 30 96.8 12 92.3
Necrotising enterocolitis at some stage 8 8
Based on clinical picture 33 7.9 29 7.5 4 12.9 1 7.7
Confirmed by X-ray 2 0.5 2 0.5 0 0.0 0 0.0
No necrotising enterocolitis 381 91.6 354 92.0 27 87.1 12 92.3
Patent ductus arteriosus 8 8
Asymptomatic 30 7.2 26 6.8 4 12.9 2 15.4
Hemodynamically significant 3 0.7 3 0.8 0 0.0 0 0.0
No patent ductus arteriosus 383 92.1 356 92.5 27 87.1 11 84.6
Glycemia 273 257 16 8
Hyperglycaemia at some stage (≥150 mg/dl) 28 18.5 20 14.7 8 53.3 1 20.0
No documented hyperglycaemia 123 81.5 116 85.3 7 46.7 4 80.0
Total days on any supplemental oxygen 11 11
None 134 32.4 130 34.0 4 15.4 1 7.7
<5 days 130 31.5 125 32.7 5 16.1 3 23.1
5–9 days 56 13.6 52 13.6 4 12.9 3 23.1
10–24 days 53 12.8 45 11.8 8 25.8 4 30.8
≥25 days 40 9.7 30 7.9 10 32.3 2 15.4
Received blood transfusion 8 8
None 299 71.9 285 74.0 14 45.2 6 46.2
Once 75 18.0 62 16.1 13 41.9 7 53.8
Multiple 42 10.1 38 9.9 4 12.9 0 0.0
ROP retinopathy of prematurity






























































































































































































































































































































































































































































































































































































































































Table 4 Univariate logistic regression analyses of risk factors in
relation to development of any retinopathy of prematurity
(ROP) versus no ROP among 424 screened premature babies
(n = 424)





Maternal age < 25 years 0.98 0.36–2.72 0.97
Positive HIV status mother 0.00 0.5
Received antenatal steroid 1.15 0.52–2.53 0.72
Primipara 0.62 0.26–1.48 0.28
Multiple birth gestation 0.78 0.32–1.86 0.57
Caesarean section 0.48 0.23–1.00 0.05
Birth place outside NICU-hospital 2.26 0.92–5.58 0.07
Male gender 0.72 0.34–1.53 0.4
Prematurity (gestational age in weeks)
Dose–response effect 3.41 1.81–6.41 <0.001
<28 5.90 1.38–25.14 0.006
28 to <32 4.37 1.84–10.35 <0.001
≥32 Baseline
Low birth weight (g)
Dose–response effect 2.25 1.48–3,41 <0.001
<1000 26.78 2.59–277.31 <0.001
1000 to <1500 7.04 0.90–55.23 0.03
1500 to <1800 4.24 0.49–36.54 0.15
≥1800 Baseline
Low Apgar score 5 min after birth
(<7)
0.59 0.13–2.59 0.48







Patent ductus arteriosus 1.82 0.59–5.57 0.29
Hyperglycaemia (≥150 mg/dl) at
some stage
6.63 2.04–21.50 <0.001
Daily weigth gain at 3th week per kg birth weight
12 g < loss < 0 g per day 1.95 0.45–8.47 0.36
0 g ≤ gain < 5 g per day 0.89 0.20–3.94 0.88
5 g ≤ gain < 10 g per day 1.42 0.35–5.70 0.62
Gain ≥ 10 g per day Baseline





pressure (CPAP) at some stage
0.82 0.37–1.83 0.63
Ventilator at some stage 5.30 1.45–19.37 0.005
Days on high flow nasal cannula oxygen
<6 days Baseline
6–16 days 0.56–5.13 0.35
17–86 days 5.83 2.24–15.22 <0.001
Dose–response effect 2.87 1.68–4.91 <0.001
Total days on any supplemental oxygen
<5 days Baseline
5–9 days 1.92 0.49–7.50 0.34
10–24 days 4.44 1.35–14.68 0.007
≥25 days 8.33 2.48–27.96 <0.001
Dose–response effect 2.13 1.49–3.04 <0.001
ROP retinopathy of prematurity
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There are some limitations in our study. For example,
loss to follow-up, which was in line with other studies from
sub-Saharan Africa [9], may have biased the findings, par-
ticularly as those not followed up were born with a lower
BW than those who were screened. Although there were no
medical costs and transport costs were reimbursed, 17.1%
of infants had insufficient screening episodes to ascertain
the occurrence of ROP. Difficulties in completing screening
following discharge from the NICU have been encountered
in other communities [35, 36]. Further sensitisation of
parents and health community on the importance of ROP
screening is mandatory to reduce loss to follow-up.
Screening before discharge from NICU even if the screen-
ing was not yet due, streamlined scheduling, and creation of
a log for all patients seen, can improve follow-up after
discharge [36, 37].
Despite offering training and follow-up sessions and the
use of standard photographs on ROP-classification, some
degree of inter-observer variability and observer bias/mea-
surement error between the study ophthalmologists cannot
be ruled out, especially for the clinically milder stages of
ROP. Furthermore, assessing the zone of vascularisation is
difficult and ceasing screening when vessels have entered
zone III might not be safe [38].
In conclusion, like in other low and middle-income
countries, ROP has become an emerging health problem in
Rwanda. It is expected that with further economic progress
and consequently improved neonatal care, more babies will
survive and hence develop ROP in sub-Saharan Africa [12].
Screening for ROP is indicated beyond the criteria recom-
mended in the 2013 American Academy screening guide-
lines [15]. Identification of several potentially modifiable
risk factors allows Ministries of Health and other organi-
sations involved in neonatal care and the prevention of
blindness in children in sub-Saharan Africa, to direct their
efforts to improve neonatal care and establish screening and
treatment for ROP.
Summary
What was known before
● ROP is a public health problem in middle-income
countries in Asia and Latin America and some countries
in South and West Africa.
What this study adds
● Although rarely seen a decade before, ROP has now
become an important cause of visual impairment in
other African countries like Rwanda, requiring pro-
grammes for screening and treatment.
● ROP screening is indicated beyond the 2013 American
Academy guidelines in this setting.
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